Literature DB >> 2540368

[Fluconazole treatment of systemic mycoses].

T Mori1, M Matsumura, T Ebe, M Takahashi, T Kohara, M Inagaki, H Isonuma, I Hibiya, T Hamamoto, K Watanabe.   

Abstract

Efficacies of fluconazole, a new triazole antifungal agent, were evaluated in 11 cases of systemic mycoses (1 case each of candiduria, pulmonary cryptococcosis, pulmonary aspergillosis, pulmonary penicilliosis and suspected fungal pulmonary infection, and 3 cases each of candidemia and Candida endophthalmitis). The clinical efficacies were excellent or good in 8 out of 9 cases and poor in 1. Side effects observed were mild with 1 incident each of gastrointestinal symptom and reversible leukopenia. This drug appears to be promising in treatment of systemic mycoses.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2540368

Source DB:  PubMed          Journal:  Jpn J Antibiot        ISSN: 0368-2781


  4 in total

1.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 2.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

3.  Allicin as a Volatile or Nebulisable Antimycotic for the Treatment of Pulmonary Mycoses: In Vitro Studies Using a Lung Flow Test Rig.

Authors:  Christina Schier; Jana Foerster Née Reiter; Monika Heupel; Philipp Dörner; Michael Klaas; Wolfgang Schröder; Lothar Rink; Alan J Slusarenko; Martin C H Gruhlke
Journal:  Int J Mol Sci       Date:  2022-06-14       Impact factor: 6.208

4.  Treatment of exogenous Candida endophthalmitis in rabbits with oral fluconazole.

Authors:  S S Park; D J D'Amico; B Paton; A S Baker
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.